Sofosbuvir and Ledipasvir Versus Sofosbuvir and Simeprevir Combination Therapy in the Management of Acute Hepatitis C: A Randomized Open Label Prospective Clinical Pilot Study. SLAM C Study, Interim Data

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study

“…Again, in acute HCV G1 monoinfection (PWID included), high SVR was demonstrated with 4 weeks of sofosbuvir/ledipasvir (SVR12 ITT 100%, 14/ 14) and 8 weeks of sofosbuvir plus simeprevir (SVR12 ITT 87%, 13/15). (29) In keeping with our findings, viral suppression was rapid with HCV RNA below the limit of detection in 93% at week 1 in both arms. Similarly, in acute HCV G1 and G4 with HIV coinfection, SVR12 ITT was 77% (20/26; relapse, n 5 3; reinfection, n 5 1; LTFU, n 5 2) following 6 weeks of sofosbuvir/ledipasvir (SVR12 per-protocol analysis 83% [20/24]).…”

Safety and efficacy of sofosbuvir‐based treatment of acute hepatitis C in end‐stage renal disease patients undergoing haemodialysis

“…However, at the time of the public health issue described herein, these regimens were unavailable in China. Sofosbuvir treatment AHC achieved an excellent SVR in the SLAM‐C and HepNet Acute HCV IV studies . However, the use of a full dose in patients requiring haemodialysis led to SOF accumulation and adverse drug reactions because of the renal route of elimination .…”

Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis

“…Patient age at the start of the analysis was 26 . All patients were assumed to be genotype 1 because this was the genotype included in the currently available studies investigating the efficacy of DAAs in the acute phase of HCV infection …”

“…In the treat acute HCV arm, after the diagnostic tests, patients received immediate treatment with 6 weeks of ledipasvir/sofosbuvir . Although two pilot studies showed 100% SVR with 4‐6 weeks of treatment with ledipasvir/sofosbuvir, these were small trials and we did not want to overestimate SVR efficacy by incorporating rates of 100%. We therefore made the assumption that the SVR rate in acute HCV treatment would at a minimum be equivalent to the SVR rate in chronic treatment and utilized SVR values from published studies on chronic HCV therapy …”

“…A number of recent and ongoing pilot trials evaluating the efficacy of DAAs in acute HCV infection are beginning to demonstrate similar positive results. In particular, two studies—the German HepNet Acute HCV IV Study and the US SLAM C Study‐showed 100% SVR with 4‐6 weeks of treatment with ledipasvir/sofosbuvir …”